Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07481-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2024. Verfasst von Umberto Pensato und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. umbertopensato91@gmail.com. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Seizures, Antigens, CD19, Anticonvulsants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Introduction
Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure medication (ASM) prevention strategy has not been thoroughly investigated.
Methods
Consecutive patients affected by refractory non-Hodgkin lymphoma who received anti-CD19 CAR T-cells were included. Patients were selected and assessed using similar internal protocols. ASM was started either as a primary prophylaxis (PP-group) before CAR T-cells infusion or as a pre-emptive therapy (PET-group) only upon the onset of neurotoxicity development.
Results
One hundred fifty-six patients were included (PP-group = 88, PET-group = 66). Overall, neurotoxicity and severe neurotoxicity occurred in 45 (29%) and 20 (13%) patients, respectively, equally distributed between the two groups. Five patients experienced epileptic events (PET-group = 3 [4%]; PP-group = 2 [2%]). For all the PET-group patients, seizure/status epilepticus occurred in the absence of overt CAR-T-related neurotoxicity, whereas patients in the PP-group experienced brief seizures only in the context of critical neurotoxicity with progressive severe encephalopathy. ASMs were well-tolerated by all patients, even without titration. No patients developed epilepsy or required long-term ASMs.
Conclusion
Our data suggest that both primary and pre-emptive anti-seizure prophylaxis are safe and effective in anti-CD19 CAR T-cell recipients. Clinical rationale suggests a possible more favourable profile of primary prophylaxis, yet no definitive conclusion of superiority between the two ASM strategies can be drawn from our study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. umbertopensato91@gmail.com.
- IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. umbertopensato91@gmail.com.
- Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
- IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy.
- BMT and Cell Therapy Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Pensato, U., Pondrelli, F., de Philippis, C., Asioli, G. M., Crespi, A., Buizza, A., Mannina, D., Casadei, B., Maffini, E., Straffi, L., Marcheselli, S., Zinzani, P. L., Bonifazi, F., Guarino, M., & Bramanti, S. (2024). Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. Neurological Sciences. https://doi.org/10.1007/s10072-024-07481-0
Vancouver
Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, et al. Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. Neurological Sciences. 2024. doi:10.1007/s10072-024-07481-0
BibTeX
@article{Pensato2024,
author = {Pensato, Umberto and Pondrelli, Federica and de Philippis, Chiara and Asioli, Gian Maria and Crespi, Alessandra and Buizza, Alessandro and Mannina, Daniele and Casadei, Beatrice and Maffini, Enrico and Straffi, Laura and Marcheselli, Simona and Zinzani, Pier Luigi and Bonifazi, Francesca and Guarino, Maria and Bramanti, Stefania},
title = {Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07481-0}
}
EUVIMED